IPO Pro - "The Ultimate Resource for IPOs"
Don't risk buying another IPO without IPO Pro.
Get your FREE TRIAL now.
Phase 1/2 precision immuno-oncology biotech developing therapies that direct T cells.
Industry: Health Care
Latest Trade: $3.37 0.00 (0.0%)
First Day Return: +49.0%
Return from IPO: -80.2%
Industry: Health Care
IPO Data | |
---|---|
IPO File Date | 01/19/2021 |
Offer Price | $17.00 |
Price Range $15.00 - $17.00 | |
Offer Shares (mm) | 6.5 |
Deal Size ($mm) | $110 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
IPO Data | |
---|---|
IPO Date | 02/11/2021 |
Offer Price | $17.00 |
Price Range $15.00 - $17.00 | |
Offer Shares (mm) | 6.5 |
Deal Size ($mm) | $110 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
Underwriters |
---|
Barclays |
Cantor Fitzgerald |
more |
Company Data | |
---|---|
Headquarters | Gaithersburg, MD, United States |
Founded | 2011 |
Employees | 44 |
Website www.neximmune.com |